Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Event: Regulation FD Disclosure regarding the release of an updated investor presentation intended for use at the JP Morgan Healthcare Conference and investor meetings.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the availability of an investor presentation (Exhibit 99.1) and does not contain audited financial statements or updated financial data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing is procedural, noting the distribution of new non-filed information via an investor presentation.
Guidance, Outlook, and Risks
- Management Commentary: The Company released an updated investor presentation to be used at the JP Morgan Healthcare Conference.
- Legal Status of Information: The information in this Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section.
- Incorporation by Reference: The content is not incorporated by reference into any Securities Act or Exchange Act filings unless expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation) for specific operational updates, pipeline progress, or financial guidance not detailed in this 8-K.
- Verify the date and content of the presentation against the JP Morgan Healthcare Conference schedule.
- Note that the presentation content is not legally "filed" and carries different liability standards than standard SEC filings.